What is Amgen Inc.'s P/E and P/B ratio?

Amgen Inc. has a P/E ratio of 27.8 and a P/B ratio of 20.69.

What is Amgen Inc.'s debt-to-equity ratio?

Amgen Inc. has a debt-to-equity ratio of 4.90.

How much does Amgen Inc. owe compared with what it owns?

Amgen Inc. owes $0.88 for every $1 it owns (balance sheet Jun 2026), which is high.

Does Amgen Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Amgen Inc..

Where can I read the latest news about Amgen Inc.?

Recent headlines about Amgen Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Amgen Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Amgen Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

Amgen Inc. (AMGN) Stock Price Analysis

Q: What is Amgen Inc.'s Positivity rank?

Amgen Inc. is ranked #6,170 of 6,774 companies globally and #3,510 of 4,000 in United States on PositoAI, with a Positivity Score of 5,775.

Amgen Inc. — Overview & Financial Snapshot

Amgen Inc. (NasdaqGS: AMGN) is a Healthcare company, ranked #6,170 of 6,774 companies globally and #3,510 of 4,000 in United States on PositoAI, with a Positivity Score of 5,775. Its market capitalisation is ₹22.83 lakh Cr ($241.81B), P/E ratio is 27.8 and P/B ratio is 20.69. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Powered by OpenAI

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.